Nuveen’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.2M | Buy |
216,047
+105,257
| +95% | +$5.36M | ﹤0.01% | 1488 |
|
|
2025
Q4 | $5.51M | Sell |
110,790
-175,257
| -61% | -$8.52M | ﹤0.01% | 1871 |
|
|
2025
Q3 | $13.7M | Buy |
286,047
+175,217
| +158% | +$7.06M | ﹤0.01% | 1376 |
|
|
2025
Q2 | $3.49M | Sell |
110,830
-23,297
| -17% | -$747K | ﹤0.01% | 2056 |
|
|
2025
Q1 | $4.39M | Hold |
134,127
| – | – | ﹤0.01% | 1993 |
|
|
2024
Q4 | $4.85M | Buy |
134,127
+903
| +0.7% | +$31.8K | ﹤0.01% | 1999 |
|
|
2024
Q3 | $4.15M | Hold |
133,224
| – | – | ﹤0.01% | 2074 |
|
|
2024
Q2 | $3.56M | Sell |
133,224
-93,808
| -41% | -$2.72M | ﹤0.01% | 2107 |
|
|
2024
Q1 | $7.74M | Buy |
227,032
+96,301
| +74% | +$2.87M | ﹤0.01% | 1753 |
|
|
2023
Q4 | $3.78M | Sell |
130,731
-99,861
| -43% | -$2.65M | ﹤0.01% | 2106 |
|
|
2023
Q3 | $6.36M | Sell |
230,592
-57,714
| -20% | -$1.76M | ﹤0.01% | 1744 |
|
|
2023
Q2 | $8.67M | Sell |
288,306
-138,674
| -32% | -$4.85M | ﹤0.01% | 1603 |
|
|
2023
Q1 | $15.5M | Buy |
426,980
+8,085
| +2% | +$311K | 0.01% | 1211 |
|
|
2022
Q4 | $14.9M | Buy |
418,895
+45,386
| +12% | +$1.58M | 0.01% | 1229 |
|
|
2022
Q3 | $12.6M | Buy |
373,509
+18,950
| +5% | +$617K | 0.01% | 1338 |
|
|
2022
Q2 | $10.3M | Sell |
354,559
-159,833
| -31% | -$4.58M | ﹤0.01% | 1491 |
|
|
2022
Q1 | $16M | Sell |
514,392
-242,239
| -32% | -$7.43M | 0.01% | 1332 |
|
|
2021
Q4 | $21.1M | Buy |
756,631
+199
| +0% | +$6.04K | 0.01% | 1203 |
|
|
2021
Q3 | $20.6M | Buy |
756,432
+290,359
| +62% | +$7.79M | 0.01% | 1252 |
|
|
2021
Q2 | $14.4M | Buy |
466,073
+172,875
| +59% | +$5.3M | ﹤0.01% | 1625 |
|
|
2021
Q1 | $7.68M | Buy |
293,198
+824
| +0.3% | +$23K | ﹤0.01% | 1939 |
|
|
2020
Q4 | $7.36M | Sell |
292,374
-4,316
| -1% | -$92.9K | ﹤0.01% | 1884 |
|
|
2020
Q3 | $6.18M | Sell |
296,690
-32,107
| -10% | -$729K | ﹤0.01% | 1804 |
|
|
2020
Q2 | $7.81M | Buy |
328,797
+12,943
| +4% | +$286K | ﹤0.01% | 1656 |
|
|
2020
Q1 | $5.68M | Buy |
315,854
+16,431
| +5% | +$345K | ﹤0.01% | 1638 |
|
|
2019
Q4 | $7.1M | Sell |
299,423
-335,068
| -53% | -$8.14M | ﹤0.01% | 1794 |
|
|
2019
Q3 | $17.4M | Buy |
634,491
+323,879
| +104% | +$9.6M | 0.01% | 1214 |
|
|
2019
Q2 | $10.3M | Buy |
310,612
+298,624
| +2,491% | +$10.2M | ﹤0.01% | 1591 |
|
|
2019
Q1 | $420K | Buy |
11,988
+4,319
| +56% | +$161K | ﹤0.01% | 863 |
|
|
2018
Q4 | $255K | Sell |
7,669
-5,796
| -43% | -$249K | ﹤0.01% | 925 |
|
|
2018
Q3 | $678K | Sell |
13,465
-14,999
| -53% | -$741K | ﹤0.01% | 808 |
|
|
2018
Q2 | $1.7M | Buy |
28,464
+7,051
| +33% | +$365K | 0.01% | 637 |
|
|
2018
Q1 | $981K | Buy |
+21,413
| New | +$894K | 0.01% | 750 |
|
|
2017
Q1 | – | Sell |
-25,105
| Closed | -$634K | – | 1469 |
|
|
2016
Q4 | $634K | Buy |
+25,105
| New | +$561K | ﹤0.01% | 1268 |
|
Other funds holding SUPN
VPM
VCM
NAMI
AC
Nuveen's SUPN Position: Q1 2026 in Review
Nuveen increased its Supernus Pharmaceuticals (SUPN) stake by 95% in Q1 2026, buying an estimated $5.36M and bringing the position to 216,047 shares worth $11.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1488.
Nuveen first reported a position in SUPN in Q4 2016 and has held it in 34 quarters since. The position peaked at $21.1M in Q4 2021. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.
- Nuveen held 216,047 shares of Supernus Pharmaceuticals worth $11.2M as of Q1 2026.
- Nuveen bought 105,257 Supernus Pharmaceuticals shares in Q1 2026, an estimated $5.36M.
- Supernus Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #1488 holding.
- Nuveen first reported a position in Supernus Pharmaceuticals in Q4 2016 and has held it in 34 quarters since.
- Nuveen's Supernus Pharmaceuticals position peaked at $21.1M in Q4 2021.
- 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.
Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.